The effective targeting of RAS-mutant acute myeloid leukemia (AML) still remains a challenge; RAS mutations are tied to relapse to targeted therapy, such as resistance to FLT3 inhibitors due to the ...

In NF1, many of these medications work by blocking a specific cell signaling pathway called Ras/MAPK that is hyperactive in cells that have lost NF1 function due to gene mutation. When this signaling ...

The researchers looked at one pathway—p38 mitogen-activated protein kinase (MAPK)—as a proof of concept, testing drugs that target this pathway. Interestingly, they discovered that a clinical ...